Rise in vaccine production by using cell line development process is expected to boost the growth of the global cell line development market at a CAGR of 11.3% during the forecast period of 2021 to 2027 :

Market Research Future (MRFR) has published a cooked research report on the “Global Cell Line Development Market” that contains the information from 2018 to 2027.


The cell line development market is expected to register a CAGR of 11.3% during the forecast period.


MRFR recognizes the following companies as the key players in the global cell line development market— American Type Culture Collection (ATCC) (US), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), Sigma-Aldrich Corporation (US), Selexis SA (Switzerland), Promega Corporation (US), Corning Inc. (US), WuXiAppTec Inc. (China) and  Sartorious AG (Germany).


Market Highlights


The global cell line development market is expected to register a CAGR of 11.3% during the forecast period and is expected to hit USD 10,829.9 million by 2027.


Cell line development is an essential part for research and biologic drug manufacturing. Cell lines are developed through the manipulation, discovery, and cloning of single cells. Cell line development is used in laboratory for drug metabolism and cytotoxicity testing as well as the study of gene function to bioproduction for vaccine, antibody, and cell therapy production. The key factors attributing to drive the market growth are rising research and development and application of the cell lines in the pharmaceutical and biotechnology industry, companies and hospitals. However, high maintenance cost and dearth of skilled staff are threat to the growth of the market. Furthermore, rising adoption of mammalian source for antibody production is likely to create market opportunity for the global market leaders.


Segment Analysis


The global cell line development market is mainly segmented into type, product, source and application. On the basis of type, the cell line development market has been sub-segmented into Primary Cell line, Hybridoma Cell line, Continuous Cell line, Recombinant Cell line. On the basis of product, the cell line development market has been segmented into Equipment, Incubators, Centrifuges, Bioreactors, Storage Equipments, Microscopes, Others and Media and Reagents. Based on source, the global cell line development  market is segmented into Mammalian Cells, Non Mammalian Cells, Insects, Amphibians. By application, the global cell line development market is segmented into Drug Discovery, Bio-production, Tissue Engineering and Others.


Access full report @ https://www.marketresearchfuture.com/reports/cell-line-development-market-9131


Regional Analysis


The global cell line development market has been segmented on the basis of region into North America, Europe, Asia-Pacific, and the Rest of the World. The North American market is further divided into the US and Canada. The European cell line development market has been segmented into Germany, France, the UK, Italy, Spain, Switzerland and the rest of Europe. The cell line development  market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World market includes the Middle East, Africa, and Latin America.


North America held the largest market share in the global cell line development market and is projected to reach USD 4,467.33 million by the end of 2027 at a CAGR of 11.51% from 2021 to 2027. The research laboratories across North America are increasingly modernizing their approach and using cell line development tools for antibody production, drug metabolism & cytotoxicity, tissue engineering, vaccine production, studying gene expression, production of therapeutic proteins, and other purposes. Moreover, the market in the region is driven by the increasing R&D in the pharmaceutical and biopharmaceutical industry, focusing on cell line development.


Asia-Pacific helds a significant market share in 2021 and is projected to witness highest growth rate at a CAGR of 13.02% from 2021 to 2027. Asia-Pacific is anticipated to be the fastest-growing regional market over the assessment period due to rapidly improving healthcare infrastructure, increasing demand for monoclonal antibodies to treat various diseases such as myocardial disease and cancer, use of cell line for vaccine development by the companies, and government support in regulating biotechnology products in this region. The countries in the region are well versed with trained resources, favorable regulatory policies, cost-effective labor, and a large pool of patients suffering from several acute and chronic illnesses.


Key Findings of the Study



  • The global cell line development market is expected to reach USD 10,829.89 million by 2027 at a CAGR of 11.3% during the forecast period.

  • Based on product, the reagents & media segment accounted for the largest market share of 67.5% in 2020.

  • By source, the mammalian segment dominated the market with a share of 74.8% in 2020.

  • On the basis of type, the hybridomas segment is anticipated to grow at the highest CAGR of 12.5% during the forecast period.

  • By application, bioproduction segment led the market with a share of 37.8% in 2020.

  • The North America region accounted for the largest share of the global market, which is majorly attributed to the increasing R&D in the pharmaceutical and biopharmaceutical industry, focusing on cell line development.

  • Some of the key players operating in the cell line development market are American Type Culture Collection (ATCC) (US), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), Sigma-Aldrich Corporation (US), Selexis SA (Switzerland), Promega Corporation (US), Corning Inc. (US), WuXiAppTec Inc. (China) and Sartorious AG (Germany).